Nemes Rush Group LLC Tg Therapeutics, Inc. Transaction History
Nemes Rush Group LLC
- $728 Billion
- Q2 2024
A detailed history of Nemes Rush Group LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Nemes Rush Group LLC holds 2,000 shares of TGTX stock, worth $47,460. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,000
Previous 2,000
-0.0%
Holding current value
$47,460
Previous $30.4 Million
16.96%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding TGTX
# of Institutions
287Shares Held
91.8MCall Options Held
1.9MPut Options Held
1.45M-
Vanguard Group Inc Valley Forge, PA13.7MShares$325 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$270 Million0.0% of portfolio
-
State Street Corp Boston, MA6.7MShares$159 Million0.01% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT3.65MShares$86.5 Million6.57% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V83.24MShares$77 Million0.07% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $3.45B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...